Literature DB >> 17684039

Blockade of chronic graft-versus-host disease by alloantigen-induced CD4+CD25+Foxp3+ regulatory T cells in nonlymphopenic hosts.

A Giorgini1, A Noble.   

Abstract

CD4(+)CD25(+) regulatory T cells (Tregs) are well known to suppress immunopathology induced in lymphopenic animals following T cell reconstitution, including acute graft-versus-host disease (GVHD) post-bone marrow transplantation. The regulatory potential of this subset in nonlymphopenic hosts and in chronic, Th2-mediated GVHD is less clear. We have generated alloantigen-specific cells from CD4(+)CD25(+) populations stimulated with MHC-disparate dendritic cells and found them to express a stable Treg forkhead box p3(+) phenotype with enhanced suppressive activity mediated by cell contact. When transferred into nonlymphopenic F1 hosts, nonspecific Tregs proliferated as rapidly as CD4(+)CD25(-) cells but displayed distinct growth kinetics in vitro. Tregs, expanded in response to alloantigen in vitro, displayed greatly enhanced suppressive activity, which was partially antigen-specific. They were effective inhibitors of chronic GVHD, blocking donor cell engraftment, splenomegaly, autoantibody production, and glomerulonephritis. CD25(+) and CD25(-) cells were equally susceptible to inhibition by immunosuppressive drugs targeting TCR signaling and rapamycin, but Tregs were resistant to inhibition by dexamethasone. The data indicate that alloantigen-driven expansion, rather than homeostatic proliferation, is key to the effectiveness of CD4(+)CD25(+) Tregs in GVHD and suggest that cellular therapy with alloantigen-induced Tregs in combination with glucocorticoid treatment would be effective in prevention of chronic GVHD after immune reconstitution.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17684039     DOI: 10.1189/jlb.0407227

Source DB:  PubMed          Journal:  J Leukoc Biol        ISSN: 0741-5400            Impact factor:   4.962


  16 in total

1.  Transferred antigen-specific T(H)17 but not T(H)1 cells induce crescentic glomerulonephritis in mice.

Authors:  Calogero Tulone; Angela Giorgini; Simon Freeley; Alice Coughlan; Michael Gregory Robson
Journal:  Am J Pathol       Date:  2011-10-08       Impact factor: 4.307

2.  Extracorporeal photopheresis in the treatment of graft-versus-host disease: evidence and opinion.

Authors:  James W Hart; Lisa H Shiue; Elizabeth J Shpall; Amin M Alousi
Journal:  Ther Adv Hematol       Date:  2013-10

3.  Graft-versus-host disease: part I. Pathogenesis and clinical manifestations of graft-versus-host disease.

Authors:  Sharon R Hymes; Amin M Alousi; Edward W Cowen
Journal:  J Am Acad Dermatol       Date:  2012-04       Impact factor: 11.527

4.  Distribution and clonality of the vα and vβ T-cell receptor repertoire of regulatory T cells in leukemia patients with and without graft versus host disease.

Authors:  Zhenyi Jin; Xiuli Wu; Shaohua Chen; Lijian Yang; Qifa Liu; Yangqiu Li
Journal:  DNA Cell Biol       Date:  2014-01-11       Impact factor: 3.311

5.  The effects of leflunomide on CD4(+)CD25 (+)Foxp3 (+) T regulatory cells in mice receiving allogeneic bone marrow transplantation.

Authors:  Di Jin; Kaizhong Duan; Lianjun Zhang; Jianxia Peng; Yong Zhao
Journal:  Inflamm Res       Date:  2011-11-05       Impact factor: 4.575

Review 6.  Biomarkers in chronic graft-versus-host disease.

Authors:  Jacob Rozmus; Kirk R Schultz
Journal:  Expert Rev Hematol       Date:  2011-06       Impact factor: 2.929

7.  A granulocyte-macrophage colony-stimulating factor and interleukin-15 fusokine induces a regulatory B cell population with immune suppressive properties.

Authors:  Moutih Rafei; Jeremy Hsieh; Simone Zehntner; Mengyang Li; Kathy Forner; Elena Birman; Marie-Noëlle Boivin; Yoon Kow Young; Claude Perreault; Jacques Galipeau
Journal:  Nat Med       Date:  2009-08-09       Impact factor: 53.440

8.  Autophagy-dependent regulatory T cells are critical for the control of graft-versus-host disease.

Authors:  Laëtitia Le Texier; Katie E Lineburg; Benjamin Cao; Cameron McDonald-Hyman; Lucie Leveque-El Mouttie; Jemma Nicholls; Michelle Melino; Blessy C Nalkurthi; Kylie A Alexander; Bianca Teal; Stephen J Blake; Fernando Souza-Fonseca-Guimaraes; Christian R Engwerda; Rachel D Kuns; Steven W Lane; Michele Teng; Charis Teh; Daniel Gray; Andrew D Clouston; Susan K Nilsson; Bruce R Blazar; Geoffrey R Hill; Kelli Pa MacDonald
Journal:  JCI Insight       Date:  2016-09-22

9.  Preclinical models of acute and chronic graft-versus-host disease: how predictive are they for a successful clinical translation?

Authors:  Robert Zeiser; Bruce R Blazar
Journal:  Blood       Date:  2016-03-18       Impact factor: 22.113

10.  In vivo-activated CD103+CD4+ regulatory T cells ameliorate ongoing chronic graft-versus-host disease.

Authors:  Dongchang Zhao; Chunyan Zhang; Tangsheng Yi; Chia-Lei Lin; Ivan Todorov; Fouad Kandeel; Stephen Forman; Defu Zeng
Journal:  Blood       Date:  2008-06-12       Impact factor: 22.113

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.